EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rat nasal mucosa‐derived ectodermal mesenchymal stem cells: A new therapeutic option for chronic rhinosinusitis

Liujin Li iD, ZhaoHui Liu, ChunLin Zhang, YiLin Long, TianWen Yang

Immunity, Inflammation and Disease · 2024

DOI: 10.1002/iid3.1337 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2024. Verfasst von Liujin Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Hospital of Zunyi Medical University, Zunyi, China. Hauptthemen laut MEDLINE: Nasal Mucosa, Sinusitis, Mesenchymal Stem Cells, Rats, Sprague-Dawley. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guizhou Provincial Health Care Commission on Provincial Medical Key Disciplines in 2023-2024, Zunyi Science and Technology Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the effect of nasal mucosa‐derived ectodermal mesenchymal stem cells (NM‐EMSCs) on the inflammatory state of rats with chronic rhinosinusitis (CRS) and the underlying therapeutic mechanism.

Methods

NM‐EMSCs were isolated and extracted to construct a rat model of CRS. Fifteen Sprague‒Dawley (SD) rats were randomly divided into three groups: CK + NS group rats were injected locally with saline in the nasal mucosa; CRS + NS group rats were injected locally with saline in the nasal mucosa; and CRS + EMSCs group rats were injected locally with NM‐EMSCs in the nasal mucosa. One rat from the CRS + EMSCs group was randomly euthanized at 2, 4, and 6 days after injection, and the nasal mucosa tissues were collected for HE staining, Masson's trichrome staining, and periodic acid–Schiff staining.

Results

NM‐EMSCs specifically expressing CD73, CD105, and CD90 were successfully isolated from the nasal mucosa of rats and were able to differentiate into adipocytes, osteoblasts, and chondrocytes. After saline and NM‐EMSC injection, compared with those in the blank control CK + NS group, the nasal mucosa in the CRS + NS and CRS + EMSC groups exhibited obvious thickening, a large amount of inflammatory cell infiltration, and increased collagen and mucin distribution. Four days post‐NM‐EMSC injection, the thickening of the nasal mucosa in the CRS group was gradually alleviated, the inflammatory cell infiltration gradually decreased, and the distribution of collagen and mucin and the collagen‐positive area gradually decreased. Moreover, only a small number of inflammatory cells were visible, and the distribution of mucins was limited to 6 days post‐NM‐EMSC injection.

Conclusion

NM‐EMSCs effectively attenuated inflammation in the nasal mucosa of CRS model rats.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasal MucosaSinusitisMesenchymal Stem CellsRats, Sprague-DawleyMesenchymal Stem Cell TransplantationRhinitisCell DifferentiationAnimalsRatsChronic DiseaseDisease Models, AnimalCells, CulturedMaleRhinosinusitis

Stichwörter der Autor:innen

NM‐EMSCscell‐based therapychronic rhinosinusitis

Autor:innen und Institutionen

  • Affiliated Hospital of Zunyi Medical University, Zunyi, China.

ORCID-Profile: Liujin Li

Förderung

  • Guizhou Provincial Health Care Commission on Provincial Medical Key Disciplines in 2023-2024
  • Zunyi Science and Technology Programme

Zitieren

APA

Li, L., Liu, Z., Zhang, C., Long, Y., & Yang, T. (2024). Rat nasal mucosa‐derived ectodermal mesenchymal stem cells: A new therapeutic option for chronic rhinosinusitis. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.1337

Vancouver

Li L, Liu Z, Zhang C, Long Y, Yang T. Rat nasal mucosa‐derived ectodermal mesenchymal stem cells: A new therapeutic option for chronic rhinosinusitis. Immunity, Inflammation and Disease. 2024. doi:10.1002/iid3.1337

BibTeX
@article{Li2024,
  author = {Li, Liujin and Liu, ZhaoHui and Zhang, ChunLin and Long, YiLin and Yang, TianWen},
  title = {Rat nasal mucosa‐derived ectodermal mesenchymal stem cells: A new therapeutic option for chronic rhinosinusitis},
  journal = {Immunity, Inflammation and Disease},
  year = {2024},
  doi = {10.1002/iid3.1337}
}
Kostenlos starten →